# US 2004/0081992 A1 · Compositions and methods for the treatment and diagnosis of cardiovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081992 A1
- Document ID: US20040081992A1
- Status: Published application
- Kind: A1
- Application number: 10/653,872
- Filed: 2003-09-03
- Published: 2004-04-29
- Earliest claimed: 1995-02-10
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Dean A. Falb; Michael A. Gimbrone JR.
- Web page: https://patentgrep.com/patent/US20040081992A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 14/47: from mammals
- C12N 9/0065: {acting on hydrogen peroxide as acceptor (1.11)}
- C12N 9/0083: {Miscellaneous (1.14.99)}
- C12N 9/0089: {acting on superoxide as acceptor (1.15)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleotide sequence (a) encoding a polypeptide having the amino acid sequence set forth in FIG. 9, or (b) encoding a polypeptide encoded by the rchd534-long cDNA contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a) or (b).

### Claim 2

An isolated polynucleotide comprising the nucleotide sequence (a) of the rchd534-long cDNA as shown in FIG. 9, or (b) of the rchd534 cDNA insert contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a).

### Claim 3 (depends on 1)

An isolated polynucleotide that hybridizes under highly stringent conditions to the nucleotide sequence of claim 1.

### Claim 4 (depends on 1)

An isolated polynucleotide that encodes a protein member of the TGF-β signalling pathway, wherein the polynucleotide hybridizes under moderately stringent conditions to the nucleotide sequence of claim 1.

### Claim 5

An isolated polynucleotide comprising the nucleotide sequence (a) of the rchd534-long polypeptide coding region, which coding region is set forth from nucleotide residue number 155 to 494 of FIG. 9, or (b) of the polypeptide coding region of the rchd534-long cDNA contained in the clone pHL6TA1A, as deposited with the American Type Culture Collection as Accession No. 209615, or (c) which is the complement of (a) or (b).

### Claim 6 (depends on 5)

An isolated polynucleotide that hybridizes under highly stringent conditions to the nucleotide sequence of claim 5.

### Claim 7 (depends on 5)

An isolated polynucleotide that encodes a protein member of the TGF-β signalling pathway, wherein the polynucleotide hybridizes under moderately stringent conditions to the nucleotide sequence of claim 5.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The isolated polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7 which is DNA.

### Claim 9 (depends on 8)

The isolated polynucleotide of claim 8 which is cDNA.

### Claim 10 (depends on 8)

The isolated polynucleotide of claim 8 which is genomic DNA.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

The isolated polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7 which is RNA.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

The isolated polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7 which further comprises a detectable label.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

A vector containing the polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6)

An expression vector containing the polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7 in operative association with a nucleotide regulatory element that controls expression of the polynucleotide in a host cell.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6)

A cultured genetically engineered host cell containing the polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6)

A cultured genetically engineered host cell containing the polynucleotide of claims 1, 2, 3, 4, 5, 6, or 7 in operative association with a nucleotide regulatory element that controls expression of the polynucleotide in the host cell.

### Claim 17 (depends on 16)

The genetically engineered host cell of claim 16 which is prokaryotic.

### Claim 18 (depends on 16)

The genetically engineered host cell of claim 16 which is eukaryotic.

### Claim 19 (depends on 17)

A method of producing an rchd534-long polypeptide, comprising the steps of:
(a) growing the genetically engineered host cell of claim 17 in a culture; and
(b) collecting the polypeptide from the culture.

### Claim 20 (depends on 18)

A method of producing an rchd534-long polypeptide, comprising the steps of:
(a) growing the genetically engineered host cell of claim 18 in a culture; and
(b) collecting the polypeptide from the culture.

### Claim 21

A method for identifying a substance for treating cardiovascular disease comprising assaying the ability of the substance to modulate the expression of the rchd534 gene, or the activity of the rchd534 or rchd534-long protein.

### Claim 22 (depends on 21)

The method of claim 21 in which the cardiovascular disease is atherosclerosis.

### Claim 23 (depends on 21)

The method of claim 21 in which the cardiovascular disease is ischemia/reperfusion.

### Claim 24 (depends on 21)

The method of claim 21 in which the cardiovascular disease is hypertension.

### Claim 25 (depends on 21)

The method of claim 21 in which the cardiovascular disease is restenosis.

### Claim 26 (depends on 21)

The method of claim 21 in which the modulation of the expression of said gene is assayed by:
(a) exposing a sample of cells to a test substance;
(b) assaying the expression of said gene in the sample of cells; and
(c) comparing the expression level of the gene in the sample exposed to the substance to the expression level of the gene in a control sample of cells, in which a difference between the expression level of the gene in the sample exposed to the substance and the control indicates the modulation of expression of the gene.

### Claim 27 (depends on 26)

The method of claim 26 in which the gene is down-regulated by the test substance.

### Claim 28 (depends on 27)

The method of claim 27 in which the substance is an oligonucleotide complementary to the 5′ region of the gene and blocks transcription via triple helix formation.

### Claim 29 (depends on 27)

The method of claim 27 in which the substance is an antisense or ribozyme molecule that blocks translation of the gene.

### Claim 30 (depends on 26)

The method of claim 26 in which the gene is up-regulated by the test substance.

### Claim 31 (depends on 21)

The method of claim 21 in which the substance is a small organic or inorganic molecule that modulates the activity of the protein product by binding to the protein product.

### Claim 32 (depends on 21)

The method of claim 21 in which the substance is an antibody that modulates the activity of the protein product by binding to the protein product.

### Claim 33

An assay for identifying a substance that binds to the rchd534-long protein, comprising:
(a) contacting a protein or peptide containing an amino acid sequence corresponding to the binding site of the protein with a test substance, under conditions and for a time sufficient to permit binding and formation of a complex between the protein or peptide and the test substance, and
(b) detecting the formation of a complex, in which the ability of the test substance to bind to the protein is indicated by the presence of the test substance in the complex.

### Claim 34

An assay for identifying a substance that inhibits the interaction between the rchd534-long protein and the fchd540 protein comprising:
(a) contacting a protein or peptide containing an amino acid sequence corresponding to the binding site of the rchd534-long protein with a protein or peptide containing an amino acid sequence corresponding-to the binding site of the fchd540 protein, under conditions and for a time sufficient to permit binding and formation of a complex, in the presence of a test substance, and
(b) detecting the formation of a complex, in which the ability of a test substance to inhibit the interaction between the rchd534-long protein and fchd540 protein is indicated by a decrease in complex formation as compared to the amount of complex formed in the absence of the test substance.

### Claim 35

An assay for identifying a substance that inhibits the interaction between two rchd534-long protein molecules comprising:
(a) contacting a first protein or peptide containing an amino acid sequence corresponding to the binding site of the rchd534-long protein with a second protein or peptide containing an amino acid sequence corresponding to the binding site of the rchd534-long protein, under conditions and for a time sufficient to permit binding and formation of a complex, in the presence of a test substance, and
(b) detecting the formation of a complex, in which the ability of a test substance to inhibit the interaction between two rchd534-long protein molecules is indicated by a decrease in complex formation as compared to the amount of complex formed in the absence of the test substance.

### Claim 36

An assay for identifying a substance that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway comprising:
(a) contacting a protein or peptide containing an amino acid sequence corresponding to the binding site of the rchd534-long protein with a protein or peptide containing an amino acid sequence corresponding to the binding site of the protein member of the TGF-β signalling pathway, under conditions and for a time sufficient to permit binding and formation of a complex, in the presence of a test substance, and
(b) detecting the formation of a complex, in which the ability of a test substance to inhibit the interaction between the rchd534-long protein and the protein member of the TGF-β signalling pathway is indicated by a decrease in complex formation as compared to the amount of complex formed in the absence of the test substance.

### Claim 37 (depends on 36)

The assay of claim 36 wherein the protein member of the TGF-β signalling pathway is MADR1, MADR2, DPC4, activated TβR1, activated ActR1b, or activated ALK6.

### Claim 38

An assay for identifying a substance that inhibits the interaction between the fchd540 protein and a protein member of the TGF-β signalling pathway comprising:
(a) contacting a protein or peptide containing an amino acid sequence corresponding to the binding site of the fchd540 protein with a protein or peptide containing an amino acid sequence corresponding to the binding site of the protein member of the TGF-β signalling pathway, under conditions and for a time sufficient to permit binding and formation of a complex, in the presence of a test substance, and
(b) detecting the formation of a complex, in which the ability of the test substance to inhibit the interaction between the fchd540 protein and the protein member of the TGF-β signalling pathway is indicated by a decrease in complex formation as compared to the amount of complex formed in the absence of the test substance.

### Claim 39 (depends on 38)

The assay of claim 38 wherein the protein member of the TGF-β signalling pathway is MADR1, MADR2, DPC4, activated TβR1, activated ALK6, activated TSR1, activated ALK3, or activated ActR1β.

### Claim 40

A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the rchd534-long protein and the fchd540 protein.

### Claim 41

A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between two rchd534-long protein molecules.

### Claim 42

A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway.

### Claim 43 (depends on 42)

The method of claim 42 wherein the protein member of the TGF-β signalling pathway is MADR1, MADR2, DPC4, activated TβR1, activated ActR1b, or activated ALK6.

### Claim 44

A method for treating cardiovascular disease comprising administering a compound that inhibits the interaction between the fchd540 protein and a protein member of the TGF-β signalling pathway.

### Claim 45 (depends on 44)

The method of claim 44 wherein the protein member of the TGF-β signalling pathway is MADR1, MADR2, DPC4, activated TβR1, activated ALK6, activated TSR1, activated ALK3, or activated ActR1β.

### Claim 46

A method for identifying a substance that enhances the TGF-β signalling response comprising:
(a) contacting a genetically engineered cell with a test substance, said cell comprising 1) a reporter gene in operative association with an inducible TGF-β regulatory element; 2) a recombinant gene encoding the rchd534-long protein or a recombinant gene encoding the fchd540 protein; and 3) a recombinant gene encoding the MADR1 protein or a recombinant gene encoding the MADR2 protein; and
(b) detecting expression of said reporter gene in which ability of the test substance to enhance the TGF-β signalling response is indicated by an increase in expression of the reporter gene as compared to the amount of expression in the absence of the test substance.

### Claim 47

A method for identifying a substance for treating fibroproliferative disease or oncogenic related disorders comprising assaying the ability of the substance to modulate expression of, or the activity of the encoded protein product of, the rchd534-long spliceoform or the fchd540 gene.

### Claim 48 (depends on 47)

The method of claim 47 in which the fibroproliferative disease is diabetic retinopathy.

### Claim 49 (depends on 47)

The method of claim 47 in which the oncogenic related disorder is a tumor growth.

### Claim 50 (depends on 47)

The method of claim 47 in which the oncogenic related disorder is angiogenesis.

### Claim 51

A method for treating fibroproliferative disease or oncogenic related disorders comprising administering a compound that inhibits the interaction between the rchd534-long protein and a protein member of the TGF-β signalling pathway.

### Claim 52

A method for treating fibroproliferative disease or compound that inhibits the interaction between the rchd534-long protein and the fchd540 protein.
